SELLAS Life Sciences Group, Inc. Increase (Decrease) in Contract with Customer, Liability
SELLAS Life Sciences Group, Inc. (SLS) reported Increase (Decrease) in Contract with Customer, Liability of $2.00 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-31.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2022-03-31
- SELLAS Life Sciences Group, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2021-12-31 was $0.00.
- SELLAS Life Sciences Group, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2021-09-30 was $0.00.
- SELLAS Life Sciences Group, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2021-06-30 was $1.00M.
- SELLAS Life Sciences Group, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2021-03-31 was $1.00M.
- SELLAS Life Sciences Group, Inc. increase (decrease) in contract with customer, liability for fiscal 2021 was $2.00M, a 73.33% decline from fiscal 2020.
- SELLAS Life Sciences Group, Inc. increase (decrease) in contract with customer, liability for fiscal 2020 was $7.50M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $0.00 derived: sum of 2 quarters · filed 2022-03-31 | $1.00M derived: sum of 3 quarters · filed 2022-03-31 | $2.00M 10-K · filed 2022-03-31 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $1.00M derived: sum of 2 quarters · filed 2021-11-12 | $2.00M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $2.00M 10-Q · filed 2021-08-12 | ||
| 2021-03-31 | $1.00M 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | $7.50M 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |